THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 121 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $83,011 | +2225.2% | 9,789 | +2359.5% | 0.00% | – |
Q1 2024 | $3,570 | -98.6% | 398 | -98.3% | 0.00% | -100.0% |
Q4 2023 | $262,274 | +542.9% | 23,334 | +393.6% | 0.00% | +200.0% |
Q3 2023 | $40,794 | -1.8% | 4,727 | +17.7% | 0.00% | 0.0% |
Q2 2023 | $41,556 | +207680.0% | 4,015 | +116.1% | 0.00% | 0.0% |
Q1 2023 | $20 | -4.8% | 1,858 | -3.3% | 0.00% | 0.0% |
Q4 2022 | $21 | -100.0% | 1,922 | -80.5% | 0.00% | -50.0% |
Q3 2022 | $100,000 | +334.8% | 9,877 | +292.4% | 0.00% | +100.0% |
Q2 2022 | $23,000 | +53.3% | 2,517 | +64.1% | 0.00% | – |
Q1 2022 | $15,000 | -21.1% | 1,534 | -12.3% | 0.00% | – |
Q4 2021 | $19,000 | -26.9% | 1,749 | -50.2% | 0.00% | -100.0% |
Q3 2021 | $26,000 | -40.9% | 3,509 | +16.0% | 0.00% | 0.0% |
Q2 2021 | $44,000 | -8.3% | 3,024 | +27.4% | 0.00% | 0.0% |
Q1 2021 | $48,000 | +92.0% | 2,374 | +65.9% | 0.00% | 0.0% |
Q4 2020 | $25,000 | -95.3% | 1,431 | -96.1% | 0.00% | -83.3% |
Q3 2020 | $537,000 | +210.4% | 36,347 | +341.2% | 0.01% | -14.3% |
Q2 2020 | $173,000 | +116.2% | 8,239 | +166.3% | 0.01% | 0.0% |
Q4 2019 | $80,000 | +128.6% | 3,094 | +72.1% | 0.01% | +250.0% |
Q3 2019 | $35,000 | +105.9% | 1,798 | +68.7% | 0.00% | +100.0% |
Q2 2019 | $17,000 | -32.0% | 1,066 | -0.1% | 0.00% | -50.0% |
Q1 2019 | $25,000 | +150.0% | 1,067 | +166.8% | 0.00% | +100.0% |
Q4 2018 | $10,000 | -16.7% | 400 | -23.5% | 0.00% | 0.0% |
Q2 2018 | $12,000 | -25.0% | 523 | -20.8% | 0.00% | 0.0% |
Q1 2018 | $16,000 | +6.7% | 660 | +20.9% | 0.00% | -50.0% |
Q4 2017 | $15,000 | -93.4% | 546 | -91.8% | 0.00% | -89.5% |
Q3 2017 | $227,000 | +383.0% | 6,654 | +458.7% | 0.02% | +280.0% |
Q2 2017 | $47,000 | +487.5% | 1,191 | +436.5% | 0.01% | +400.0% |
Q1 2017 | $8,000 | +166.7% | 222 | +167.5% | 0.00% | – |
Q4 2016 | $3,000 | -40.0% | 83 | -63.8% | 0.00% | – |
Q2 2016 | $5,000 | +150.0% | 229 | +84.7% | 0.00% | – |
Q4 2015 | $2,000 | – | 124 | +1140.0% | 0.00% | – |
Q1 2015 | $0 | -100.0% | 10 | -76.2% | 0.00% | – |
Q3 2014 | $1,000 | -83.3% | 42 | -75.9% | 0.00% | -100.0% |
Q2 2014 | $6,000 | – | 174 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |